[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT3360864T - Composto de pirimidina - Google Patents

Composto de pirimidina

Info

Publication number
PT3360864T
PT3360864T PT168536860T PT16853686T PT3360864T PT 3360864 T PT3360864 T PT 3360864T PT 168536860 T PT168536860 T PT 168536860T PT 16853686 T PT16853686 T PT 16853686T PT 3360864 T PT3360864 T PT 3360864T
Authority
PT
Portugal
Prior art keywords
pyrimidine compound
pyrimidine
compound
Prior art date
Application number
PT168536860T
Other languages
English (en)
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of PT3360864T publication Critical patent/PT3360864T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • C07D239/49Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Oncology (AREA)
PT168536860T 2015-10-07 2016-10-06 Composto de pirimidina PT3360864T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015199750 2015-10-07

Publications (1)

Publication Number Publication Date
PT3360864T true PT3360864T (pt) 2021-06-02

Family

ID=58487860

Family Applications (2)

Application Number Title Priority Date Filing Date
PT211646401T PT3868741T (pt) 2015-10-07 2016-10-06 Composição compreendendo um composto de pirimidina e um antigénio derivado de agente patogénico
PT168536860T PT3360864T (pt) 2015-10-07 2016-10-06 Composto de pirimidina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT211646401T PT3868741T (pt) 2015-10-07 2016-10-06 Composição compreendendo um composto de pirimidina e um antigénio derivado de agente patogénico

Country Status (21)

Country Link
US (4) US10632192B2 (pt)
EP (2) EP3360864B1 (pt)
JP (3) JP6769976B2 (pt)
KR (1) KR102651207B1 (pt)
CN (1) CN108290845B (pt)
AU (1) AU2016334826B2 (pt)
CA (1) CA3001283C (pt)
CY (1) CY1124542T1 (pt)
DK (2) DK3868741T3 (pt)
ES (2) ES2960724T3 (pt)
FI (1) FI3868741T3 (pt)
HK (1) HK1255921A1 (pt)
HU (2) HUE055079T2 (pt)
MY (1) MY194902A (pt)
PH (1) PH12018500755A1 (pt)
PL (2) PL3868741T3 (pt)
PT (2) PT3868741T (pt)
RU (1) RU2759917C2 (pt)
SG (1) SG11201802832UA (pt)
TW (1) TWI718188B (pt)
WO (1) WO2017061532A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6769976B2 (ja) 2015-10-07 2020-10-14 大日本住友製薬株式会社 ピリミジン化合物
IL308894A (en) 2016-10-14 2024-01-01 Prec Biosciences Inc Transgenic meganonucleases specific for recognition sequences in the hepatitis B virus genome
EP3554474B1 (en) * 2016-12-16 2023-12-06 Baxter International Inc. Micafungin compositions
CN110650729B (zh) 2017-03-29 2024-08-20 住友制药株式会社 疫苗佐剂制剂
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. Stingアダプタータンパク質を活性化するホスホン酸結合を有する3’3’環状ジヌクレオチド
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
MX2021000951A (es) 2018-07-23 2021-06-23 Sumitomo Pharma Co Ltd Composición que contiene vacuna contra la influenza.
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
UA126619C2 (uk) 2018-10-31 2022-11-02 Гіліад Сайєнсіз, Інк. Заміщені сполуки 6-азабензімідазолу як інгібітори hpk1
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
BR112021011495A8 (pt) * 2018-12-26 2022-12-06 Sumitomo Dainippon Pharma Co Ltd Preparação incluindo adjuvante para vacina
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
KR20220004637A (ko) 2019-04-05 2022-01-11 다이닛본 스미토모 세이야꾸 가부시끼가이샤 수용성 보조제
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
PE20221111A1 (es) 2019-09-30 2022-07-11 Gilead Sciences Inc Vacunas para vhb y metodos de tratamiento de vhb
EP4069729B1 (en) 2019-12-06 2025-01-22 Precision BioSciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
KR20220156884A (ko) 2020-03-20 2022-11-28 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
JP2023520376A (ja) * 2020-03-27 2023-05-17 ピーエイティエイチ マラリア伝搬阻止ワクチン
AU2022274607A1 (en) 2021-05-13 2023-11-16 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
WO2024214771A1 (ja) * 2023-04-12 2024-10-17 住友ファーマ株式会社 デキストランとtlr7アゴニストのコンジュゲート体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ATE267175T1 (de) 1998-08-27 2004-06-15 Sumitomo Pharma Pyrimidin derivate
WO2005001022A2 (en) 2003-04-10 2005-01-06 3M Innovative Properties Company Methods and compositions for enhancing immune response
AU2004266657B2 (en) 2003-08-14 2009-07-02 3M Innovative Properties Company Lipid-modified immune response modifiers
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
FR2924024B1 (fr) * 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
BRPI0919937A2 (pt) 2008-10-24 2016-02-16 Glaxosmithkline Biolog Sa composto, e, método para melhorar a atividade de adjuvante de uma imidazoquinolina
FR2937549B1 (fr) * 2008-10-29 2011-04-01 Centre Nat Rech Scient Nanoparticules de derives beta-lactamine
SG173617A1 (en) 2009-02-11 2011-09-29 Univ California Toll-like receptor modulators and treatment of diseases
JP5206513B2 (ja) 2009-03-12 2013-06-12 オムロンヘルスケア株式会社 機能追加モジュール
EA201101650A1 (ru) * 2009-05-21 2012-07-30 Астразенека Аб Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
ES2732999T3 (es) 2009-08-07 2019-11-27 Glaxosmithkline Biologicals Sa Derivados de oxoadenina lipidada
CN103118682A (zh) 2010-04-30 2013-05-22 加利福尼亚大学校务委员会 合成tlr7激动剂的磷脂缀合物的用途
PL2606047T3 (pl) * 2010-08-17 2017-07-31 3M Innovative Properties Company Kompozycje, preparaty i sposoby obejmujące lipidowane związki modyfikujące odpowiedź immunologiczną
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
WO2012066335A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
US20130267532A1 (en) * 2010-11-19 2013-10-10 Shinya Tosaki Cyclic amide compounds and their use in the treatment of disease
WO2012067269A1 (en) * 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
MX2014002949A (es) * 2011-09-20 2014-04-30 Hoffmann La Roche Compuesto de imidazopiridina, composiciones y metodos de uso.
TWI619704B (zh) * 2012-05-18 2018-04-01 大日本住友製藥股份有限公司 羧酸化合物
JP6769976B2 (ja) 2015-10-07 2020-10-14 大日本住友製薬株式会社 ピリミジン化合物

Also Published As

Publication number Publication date
PT3868741T (pt) 2023-10-19
KR102651207B1 (ko) 2024-03-25
EP3360864B1 (en) 2021-04-28
US20180280499A1 (en) 2018-10-04
TW201718518A (zh) 2017-06-01
CA3001283A1 (en) 2017-04-13
MY194902A (en) 2022-12-22
SG11201802832UA (en) 2018-05-30
RU2018116351A3 (pt) 2020-02-25
ES2960724T3 (es) 2024-03-06
JP6769976B2 (ja) 2020-10-14
US20220226468A1 (en) 2022-07-21
PL3868741T3 (pl) 2024-01-29
PL3360864T3 (pl) 2021-10-25
EP3868741B1 (en) 2023-08-30
US10632192B2 (en) 2020-04-28
JP2021001210A (ja) 2021-01-07
RU2759917C2 (ru) 2021-11-18
JPWO2017061532A1 (ja) 2018-08-02
US11266738B2 (en) 2022-03-08
CY1124542T1 (el) 2022-07-22
KR20180056774A (ko) 2018-05-29
EP3360864A1 (en) 2018-08-15
AU2016334826A1 (en) 2018-05-10
US11911466B2 (en) 2024-02-27
DK3360864T3 (da) 2021-06-14
EP3868741A1 (en) 2021-08-25
TWI718188B (zh) 2021-02-11
JP2022010266A (ja) 2022-01-14
HUE055079T2 (hu) 2021-10-28
CN108290845B (zh) 2021-08-03
DK3868741T3 (da) 2023-11-06
FI3868741T3 (fi) 2023-10-02
RU2018116351A (ru) 2019-11-07
US20210008197A1 (en) 2021-01-14
US20240245766A1 (en) 2024-07-25
CN108290845A (zh) 2018-07-17
HK1255921A1 (zh) 2019-09-06
AU2016334826B2 (en) 2020-08-27
HUE064322T2 (hu) 2024-03-28
PH12018500755A1 (en) 2018-10-15
JP7195398B2 (ja) 2022-12-23
WO2017061532A1 (ja) 2017-04-13
CA3001283C (en) 2023-10-10
EP3360864A4 (en) 2019-05-29
ES2870679T3 (es) 2021-10-27

Similar Documents

Publication Publication Date Title
HK1255921A1 (zh) 嘧啶化合物
GB201510019D0 (en) Compounds
IL250022A0 (en) New converted pyrimidine compounds
GB201514751D0 (en) Compounds
GB201508747D0 (en) Compounds
HK1255832A1 (zh) 吡喃並二吡啶化合物
GB201521524D0 (en) Compound
AP2016009506A0 (en) Pyrimidine compound
GB201508864D0 (en) Compounds
SG10201913525QA (en) Pyrimidine derivative
GB201510493D0 (en) Compounds
HUE056942T2 (hu) Pirimidin vegyület
GB201503926D0 (en) Compounds
GB201518950D0 (en) Compound
GB201508857D0 (en) Compounds
GB201501115D0 (en) Compounds
HK1251574A1 (zh) 四氫噁庚英吡啶化合物
GB201520393D0 (en) Compound
GB201520391D0 (en) Compound
GB201509303D0 (en) Compound
GB201512279D0 (en) Compounds
GB201511387D0 (en) Compounds
GB201511064D0 (en) Compounds
GB201510910D0 (en) Compounds
GB201510760D0 (en) Compounds